Abstract
The educational cycle "Venus of The Future: the discoveries and new traditions in the treatment of mBC" was initiated by Pfizer with the support of TS Oncology. During several web-conferences planned in 20212022 key experts discussed implementation in clinical practice and availability of innovative approaches for treatment patients with HER-negative mBC in the Russian Federation. The first web-conference of the cycle - "Innovations in practice. 5 years of palbociclib experience in the Russian Federation" took place on October 8, 2021 and was dedicated to the 5th anniversary since registration in the Russian Federation of palbociclib 1st CDK4/6 inhibitor (CDK4/6i) in our country. Key Russian experts in oncology, who were at the forefront of introducing CDK4/6i into routine clinical practice, took part in the event and outlined the importance of considering the differences among iCDK 4/6 in terms of the tolerance profile and monitoring requirements, as well as taking into account practical experience when making desicion to choose specific product. Experts agreed that palbociclib have a great advantage over other products in the class due to significant amount of RCT and RWE data, as well as broad practical experience (more than 5 years) in the Russian Federation and in the world.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
